The reduction in CD38 expression level is not limited to the MM cells: all PBMC subsets show a uniform reduction in CD38 expression during treatment with daratumumab monotherapy, as well as during treatment with DRd [12]. The gene discussed is CD38; the disease is Miyoshi myopathy.